Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
FCFS First Cash Financial $84.25 1.225 (1.48%) , TWNK Hostess Brands $11.42 (0.00%) … 10:37 09/26/18 09/26 10:37 09/26/18 10:37 Initiation	On The Fly: Top five analyst initiations » Catch up on today's… Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. First Cash Financial (FCFS) initiated with an Overweight at Barclays. 2. Hostess Brands (TWNK) initiated with a Neutral at Citi. 3. Repligen (RGEN) initiated with a Neutral at H.C. Wainwright. 4. Evofem (EVFM) initiated with an Overweight at Cantor Fitzgerald. 5. Elanco (ELAN) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. FCFS First Cash Financial $84.25 1.225 (1.48%) TWNK Hostess Brands $11.42 (0.00%) RGEN Repligen $54.10 -0.25 (-0.46%) EVFM Evofem $4.33 0.1 (2.36%) ELAN Elanco $34.89 0.24 (0.69%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	26 Sep 26 Sep 01 Oct 30 Oct 06 Nov 06 Nov
RGEN Repligen $54.35 -0.71 (-1.29%) 07:08 09/26/18 09/26 07:08 09/26/18 07:08 Initiation	Repligen initiated at H.C. Wainwright » Repligen initiated with a… Repligen initiated with a Neutral at H.C. Wainwright. H.C. Wainwright analyst Raghuram Selvaraju started Repligen with a Neutral rating and $49 price target. The analyst views the shares as "pricey" at current levels, but would view the stock as attractive into the low $40s. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Nov
RGEN Repligen $55.16 -1.67 (-2.94%) 07:16 09/24/18 09/24 07:16 09/24/18 07:16 Recommendations	Repligen analyst commentary at JPMorgan » Repligen price target… Repligen price target raised to $60 from $55 at JPMorgan. JPMorgan analyst Tycho Peterson raised his price target for Repligen to $60 following meetings with management. The analyst came away with reinforced confidence in the company's "strategic direction, strong competitive positioning, and sustainable growth momentum." He remains positive on the long-term outlook of the bioprocessing market and keeps an Overweight rating on Repligen shares. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	06 Nov
RGEN Repligen $57.68 0.24 (0.42%) 04:55 09/20/18 09/20 04:55 09/20/18 04:55 Conference/Events	Repligen management to meet with JPMorgan » Meeting to be held in… Meeting to be held in Atlanta on September 20 hosted by JPMorgan. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Sep 06 Nov
RGEN Repligen $57.29 -1.7 (-2.88%) 20:20 09/17/18 09/17 20:20 09/17/18 20:20 Conference/Events	Repligen management to meet with JPMorgan » Meeting to be held in… Meeting to be held in Atlanta on September 20 hosted by JPMorgan. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	20 Sep 06 Nov

Over a month ago
RGEN Repligen $48.06 -0.24 (-0.50%) 07:35 08/02/18 08/02 07:35 08/02/18 07:35 Earnings	Repligen backs FY18 adj. EPS view of 69c-73c, consensus 71c » Raises FY18 revenue… Raises FY18 revenue guidance to $185M-$190M from $182M-$188M, consensus $185.35M. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	02 Aug
RGEN Repligen $48.06 -0.24 (-0.50%) 07:32 08/02/18 08/02 07:32 08/02/18 07:32 Earnings	Repligen reports Q2 adj. EPS 16c, consensus 18c » Reports Q2 revenue… Reports Q2 revenue $47.7M, consensus $46.08M. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	02 Aug
RGEN Repligen $48.76 0.83 (1.73%) 07:21 07/20/18 07/20 07:21 07/20/18 07:21 Recommendations	Repligen analyst commentary at Citi » Repligen price target… Repligen price target raised to $56 from $45 at Citi. Citi analyst Daniel Arias raised his price target for Repligen to $56 saying the company's momentum can continue as it pushes further into a "healthy bioproduction end market with an improved portfolio." The analyst believes Repligen shares have a "solid runway and good upside potential." Arias keeps a Buy rating on the name. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	02 Aug

Over a quarter ago
RGEN Repligen $48.03 0.14 (0.29%) 04:55 07/12/18 07/12 04:55 07/12/18 04:55 Conference/Events	Repligen management to meet with Jefferies » Meetings to be held in… Meetings to be held in Montreal on July 12 and in Toronto in July 13 hosted by Jefferies. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Jul 13 Jul
RGEN Repligen $47.89 -0.17 (-0.35%) 04:55 07/11/18 07/11 04:55 07/11/18 04:55 Conference/Events	Repligen management to meet with Jefferies » Meetings to be held in… Meetings to be held in Montreal on July 12 and in Toronto in July 13 hosted by Jefferies. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	12 Jul 13 Jul

On The Fly

News and insights, exclusive to thefly.com

20:25	Notable companies reporting before tomorrow's open»
18:55	Fly Intel: After Hours Movers»
16:24	Fly Intel: Wall Street's top stories for Tuesday»
13:31	Game On: Pachter says 'Red Dead Online' could be 25% as popular as 'GTA Online'»
13:19	Fly Intel: What to watch for in IBM's earnings report»

View all On The Fly Stories »

Upcoming
Events (10)

ITUS	Pre-IND Meeting with FDA & ITUS Corp
	Adobe MAX
A ...	ASHG Conference 2018
	2018 HCIT & Distribution Roundtable
	Gartner Symposium: ITxpo 2018
	Teradata Analytics Universe
	3-D Printing Field Trip
GNTX ...	NBAA Business Aviation Convention & Exhibition (NBAA-BACE)
XLNX ...	Arm TechCon 2018
	Advertising and Promotion for Medical Products Conference

View all of today’s events »

Today’s
Syndicate (0)

No syndicate deals.

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial